Cargando…

Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy

Hyperglycemia-induced oxidative stress plays a key role in the impairment of the retinal neurovascular unit, an early event in the pathogenesis of DR. The aim of this study was to assess the antioxidant properties of topical administration (eye drops) of sitagliptin in the diabetic retina. For this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramos, Hugo, Bogdanov, Patricia, Huerta, Jordi, Deàs-Just, Anna, Hernández, Cristina, Simó, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312245/ https://www.ncbi.nlm.nih.gov/pubmed/35883908 http://dx.doi.org/10.3390/antiox11071418

Ejemplares similares

Minimum Effective Dose of DPP-4 Inhibitors for Treating Early Stages of Diabetic Retinopathy in an Experimental Model
por: Bogdanov, Patricia, et al.
Publicado: (2022)

Transcriptomic Analysis Reveals That Retinal Neuromodulation Is a Relevant Mechanism in the Neuroprotective Effect of Sitagliptin in an Experimental Model of Diabetic Retinopathy
por: Ramos, Hugo, et al.
Publicado: (2022)

Neuromodulation Induced by Sitagliptin: A New Strategy for Treating Diabetic Retinopathy
por: Ramos, Hugo, et al.
Publicado: (2021)

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes
por: Simó, Rafael, et al.
Publicado: (2021)

Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy
por: Simó, Rafael, et al.
Publicado: (2021)

New Insights into the Mechanisms of Action of Topical Administration of GLP-1 in an Experimental Model of Diabetic Retinopathy
por: Sampedro, Joel, et al.
Publicado: (2019)

Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities: Involvement of Oxidative Stress
por: Ramos, Hugo, et al.
Publicado: (2020)

New Insights into Treating Early and Advanced Stage Diabetic Retinopathy
por: Simó, Rafael, et al.
Publicado: (2022)

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
por: Dietrich, Nadine, et al.
Publicado: (2016)

Topical ocular administration of DPP-IV inhibitors: a new approach for treating diabetes-induced retinal neurodegeneration
por: Simó, Rafael, et al.
Publicado: (2023)

Caffeine and the Risk of Diabetic Retinopathy in Type 2 Diabetes Mellitus: Findings from Clinical and Experimental Studies
por: Alcubierre, Nuria, et al.
Publicado: (2023)

Effect of Topical Administration of Somatostatin on Retinal Inflammation and Neurodegeneration in an Experimental Model of Diabetes
por: Hernández, Cristina, et al.
Publicado: (2020)

Proapoptotic and survival signaling in the neuroretina at early stages of diabetic retinopathy
por: Valverde, Angela M., et al.
Publicado: (2013)

Advances in the Medical Treatment of Diabetic Retinopathy
por: Simó, Rafael, et al.
Publicado: (2009)

Genetics in Diabetic Retinopathy: Current Concepts and New Insights
por: Simó-Servat, Olga, et al.
Publicado: (2013)

Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology
por: Simó-Servat, Olga, et al.
Publicado: (2016)

Usefulness of the Vitreous Fluid Analysis in the Translational Research of Diabetic Retinopathy
por: Simó-Servat, Olga, et al.
Publicado: (2012)

Effects of Liposomal Formulation of Citicoline in Experimental Diabetes-Induced Retinal Neurodegeneration
por: Bogdanov, Patricia, et al.
Publicado: (2018)

What else can we do to prevent diabetic retinopathy?
por: Simó, Rafael, et al.
Publicado: (2023)

Topical Administration of Bosentan Prevents Retinal Neurodegeneration in Experimental Diabetes
por: Bogdanov, Patricia, et al.
Publicado: (2018)

Neuroprotection as a Therapeutic Target for Diabetic Retinopathy
por: Hernández, Cristina, et al.
Publicado: (2016)

Mechanisms of retinal neuroprotection of calcium dobesilate: therapeutic implications
por: Simó-Servat, Olga, et al.
Publicado: (2017)

Iron Overload in Diabetic Retinopathy: A Cause or a Consequence of Impaired Mechanisms?
por: Ciudin, Andreea, et al.
Publicado: (2010)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

A DPP-4 Inhibitor Suppresses Fibrosis and Inflammation on Experimental Autoimmune Myocarditis in Mice
por: Hirakawa, Hiroyuki, et al.
Publicado: (2015)

Inflammation: The Link between Neural and Vascular Impairment in the Diabetic Retina and Therapeutic Implications
por: Ramos, Hugo, et al.
Publicado: (2023)

State-of-the-Art Research on Diabetic Retinopathy
por: Simó, Rafael
Publicado: (2022)

The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial
por: Hernández, Cristina, et al.
Publicado: (2020)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

SOCS1-Derived Peptide Administered by Eye Drops Prevents Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes
por: Hernández, Cristina, et al.
Publicado: (2019)

Proteomic Analysis of Early Diabetic Retinopathy Reveals Mediators of Neurodegenerative Brain Diseases
por: Sundstrom, Jeffrey M., et al.
Publicado: (2018)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

The Retinal Pigment Epithelium: Something More than a Constituent of the Blood-Retinal Barrier—Implications for the Pathogenesis of Diabetic Retinopathy
por: Simó, Rafael, et al.
Publicado: (2010)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria
por: Haluzík, Martin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7ega3913tsjmq37hrkt18bvemg